Publications by authors named "Joe Lawson"
Article Synopsis
- The study analyzed survival rates in patients with castration-resistant prostate cancer (CRPC) using data from Stockholm's PSA and Biopsy Registers from 2003 to 2015.
- Median overall survival after CRPC onset was 23.2 months for patients without metastases at diagnosis (M0) and 13.2 months for those with metastases (M1).
- Higher Gleason scores at diagnosis correlated with increased mortality post-CRPC, and patients diagnosed after 2012 had improved survival rates compared to those diagnosed earlier.
Background: Metastasis-free survival (MFS) has been shown to be predictive of overall survival (OS) in hormone-sensitive localized prostate cancer. We evaluated the relationship between MFS and OS in nonmetastatic castration-resistant prostate cancer (nmCRPC).
Patients And Methods: A retrospective analysis of 1207 high-risk patients with nmCRPC from the SPARTAN study (clinicaltrials.
Purpose: We sought to explore the symptomatic experience of men recently told their castration-resistant prostate cancer has metastasized (mCRPC); the impact and emotional response to this; the emotional burden of monitoring development to metastatic status; and the emotional impact on the primary support person (PSP).
Methods: Interviews were conducted with 25 men recently diagnosed with mCRPC from the United States (US), France, and Germany. We also interviewed 14 PSPs.
Background: In the SPARTAN trial, addition of apalutamide to androgen deprivation therapy, as compared with placebo plus androgen deprivation therapy, significantly improved metastasis-free survival in men with non-metastatic castration-resistant prostate cancer who were at high risk for development of metastases. We aimed to investigate the effects of apalutamide versus placebo added to androgen deprivation therapy on health-related quality of life (HRQOL).
Methods: SPARTAN is a multicentre, international, randomised, phase 3 trial.
Context: Until recently, there has been a lack of evidence-based treatment alternatives in men with nonmetastatic castrate-resistant prostate cancer (NM-CRPC). However, new evidence-based treatment alternatives are emerging.
Objective: We aimed to describe time-to-event outcomes in NM-CRPC patients based on evidence from both prospective and retrospective studies.